| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8715641 | Journal of Dermatological Science | 2018 | 9 Pages |
Abstract
Our analysis provided evidence that dupilumab had an acceptable safety profile and resulted in clinically relevant improvements in signs and symptoms of AD. Dose regimens of 300â¯mg qw and q2â¯w seemed to have similar benefits. Further long-term trials are required for confirmation.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Fa-Ping Wang, Xiao-Ju Tang, Chuan-Qi Wei, Lin-Rui Xu, Hui Mao, Feng-Ming Luo,